Original
Anastrozole (Anastron) 0.5 mg
Anastron (Anastrozole) 0.5 mg is Utinon's reversible aromatase inhibitor, supplied as 100 tablets. Factory-sealed pack with a scratch-off authenticity code.
Product Details
Key specs at a glance
Shipping & Logistics
Utinon — Europe shipping
DHL Tracked across Europe - 2 to 5 working days — $30.00 shipping (DHL Tracked)
Ships to 21 countries across Europe only. Luxembourg is accepted, but delivery is not guaranteed. We do not ship to Czech Republic, Denmark, Estonia, Finland, Latvia or Sweden.
Secure Shopping
Your data is protected with the highest security standards.Want to buy Wholesale?
Get exclusive discounts on orders over $1,500 — contact us.Description
Anastron (Anastrozole) 0.5 mg is Utinon's reversible aromatase inhibitor, supplied as 100 tablets. Anastrozole is the active compound in Arimidex and works by blocking the conversion of androgens to oestradiol. Each box is sealed and carries a scratch-off authenticity code inside.
What Anastron 0.5MG Is
Anastrozole is a non-steroidal, type II aromatase inhibitor. It binds the aromatase enzyme reversibly and with high affinity, interrupting the conversion of androstenedione and testosterone into oestrone and oestradiol. A box holds 100 tablets at 0.5 mg, for 50 mg total. The 0.5 mg unit is half the common 1 mg clinical strength, which allows finer adjustment.
The History of Arimidex
Zeneca developed anastrozole and approved it in 1995 under the Arimidex name for advanced breast cancer in postmenopausal women. The ATAC programme later compared it with tamoxifen in early disease and reported better disease-free survival, which moved aromatase inhibitors into first-line use. It is now one of the most studied endocrine agents in oncology.
How It Works
Aromatase converts androgens to oestrogens in fat, muscle and other peripheral tissues. Anastrozole occupies the enzyme binding site and blocks that step, lowering oestrogen production. The pituitary can respond with increased gonadotropin output. Absorption is reliable, hepatic metabolism dominates clearance, and the terminal half-life runs to roughly two days. Because inhibition is competitive, enzyme activity returns once the drug clears.
What the Research Shows
- ATAC established anastrozole's advantage over tamoxifen in early breast cancer.
- Standard doses produce sustained falls in circulating oestradiol.
- Long-term follow-up has tracked bone mineral density and lipid changes.
- Reversible inhibition is the key pharmacological contrast with exemestane.
Research Context
Anastrozole is a common comparator when new aromatase inhibitors are studied because its reversible kinetics are easy to model. Researchers have examined how far oestradiol must fall before bone turnover accelerates, and how quickly enzyme activity recovers after the drug is stopped. Those questions matter in any long-term oestrogen-control design, and they are why anastrozole remains a reference compound. The 0.5 mg tablet is useful where a smaller adjustment is wanted than the 1 mg clinical unit allows.
Strength, Pack and Authentication
Each tablet contains 0.5 mg of anastrozole, and the box holds 100 tablets. The carton is printed and tamper-evident, stating the compound, strength and tablet count. A scratch-off security code inside the box links the pack to Utinon's manufacturing records, and the blister format keeps every tablet protected from moisture and light until it is used.
Buying Anastron 0.5MG Online
Anastron 0.5MG is one of the most searched oestrogen-control compounds in the Utinon range. If you are researching anastrozole, comparing 0.5MG products or looking to buy Utinon Anastron online from a verified European supplier, this page gives the full specification, pack size, price and live stock status. Browse more Utinon Anti Estrogens at NotNatty.
Tags: Utinon, Anti Estrogens, arimidex-anastrozole, Anastrozole, 0.5MG, Tablet
Customers Also Bought
People Also Bought
Customer Reviews
No reviews yet
Be the first to rate this product and help the community.
Only signed-in members can leave reviews.
Sign In to Review






